Validated stability-indicating spectrofluorimetric methods for the determination of ebastine in pharmaceutical preparations

Table 8 Determination of ebastine in its dosage forms by SFS using method IIB

Proposed method				Comparison method³
Preparation	Amount found (μg/ml)	Amount found (μg/ml)	%Recovery	%Recovery
Bastab ^® tablets containing 20 mg ebastine/tablet	0.1	0.099	99.28	99.23
	0.3	0.299	99.84	99.61
	0.5	0.503	100.66	100.61
	0.7	0.703	100.43
	0.9	0.903	100.39
	1.0	0.998	99.77
X¯ ± SD			100.06 ± 0.52	99.82 ± 0.71
Student's t test			0.35(2.31)*
Variance ratio F test			1.86(5.79)*
Evastine ^® syrup containing 5 mg ebastine/5ml	0.1	0.1001	100.06	100.12
	0.3	0.298	99.64	99.61
	0.5	0.499	99.87	99.51
	0.7	0.704	100.59
	0.9	0.901	100.11
	1.0	1.007	100.74
X¯ ± SD			100.17 ± 0.42	99.75 ± 0.33
Student's t test			0.24(2.31)*
Variance ratio F test			1.62(5.79)*

ISSN: 2661-801X